Stock Events

Stock Events

Ocular Therapeutix 

$10.68
66
+$0.04+0.41% 13:07 Today

Statistics

Day High
10.66
Day Low
10.63
52W High
16.44
52W Low
6.23
Volume
89,955
Avg. Volume
-
Mkt Cap
2.34B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.4
-0.36
-0.33
-0.29
Expected EPS
-0.364417
Actual EPS
N/A

Financials

-511.9%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
51.95MRevenue
-265.94MNet Income

Analyst Ratings

27.00Average Price Target
The highest estimate is 30.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OCUL. It's not an investment recommendation.
Apple
10
AAPL
Realty Income
10
O
Amazon
10
AMZN
Bitcoin
9
BTC.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes with Ocular Therapeutix in the eye care market, particularly in treatments for eye diseases and conditions.
Novartis
NVS
Mkt Cap292.35B
Novartis provides advanced eye care treatments, including gene therapy for retinal diseases, directly competing with Ocular Therapeutix's eye disease treatments.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, through its acquisition of Allergan, competes in the ophthalmology space, particularly in treatments for eye conditions that overlap with Ocular Therapeutix's portfolio.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies, through its eye health division, offers products that compete across a broad range of eye conditions treated by Ocular Therapeutix.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Vision Care division, competes in the market for eye health, offering products that can overlap with Ocular Therapeutix's therapeutic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a presence in the ophthalmology market, competing indirectly with Ocular Therapeutix through its various treatments for eye diseases.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO is involved in gene therapy for eye diseases, representing a direct competitor to Ocular Therapeutix's approach to treating similar conditions.
EyePoint
EYPT
Mkt Cap386.23M
EyePoint Pharmaceuticals focuses on sustained release drug delivery for eye diseases, directly competing with Ocular Therapeutix's drug delivery technology.

About

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Show more...
CEO
Pravin U. Dugel
Employees
325
Country
United States
ISIN
US67576A1007
WKN
000A1180P

Listings

STU
DE
0OT.STU
F
DE
0OT.F
BOATS
BOATS
OCUL.BOATS
XNAS
US
OCUL

0 Comments

Share your thoughts

FAQ

What is Ocular Therapeutix stock price today?▼
The current price of OCUL is $10.68 USD — it has increased by +0.41% in the past 24 hours. Watch Ocular Therapeutix stock price performance more closely on the chart.
What is Ocular Therapeutix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ocular Therapeutix stocks are traded under the ticker OCUL.
Is Ocular Therapeutix stock price growing?▼
OCUL stock has risen by +2.7% compared to the previous week, the month change is a +23.86% rise, over the last year Ocular Therapeutix has showed a -16.22% decrease.
What is Ocular Therapeutix market cap?▼
Today Ocular Therapeutix has the market capitalization of 2.34B
When is the next Ocular Therapeutix earnings date?▼
Ocular Therapeutix is going to release the next earnings report on November 09, 2026.
What were Ocular Therapeutix earnings last quarter?▼
OCUL earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.4 USD resulting in a +11.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ocular Therapeutix revenue for the last year?▼
Ocular Therapeutix revenue for the last year amounts to 51.95M USD.
What is Ocular Therapeutix net income for the last year?▼
OCUL net income for the last year is -265.94M USD.
How many employees does Ocular Therapeutix have?▼
As of September 04, 2026, the company has 325 employees.
In which sector is Ocular Therapeutix located?▼
Ocular Therapeutix operates in the Health & Wellness sector.
When did Ocular Therapeutix complete a stock split?▼
Ocular Therapeutix has not had any recent stock splits.
Where is Ocular Therapeutix headquartered?▼
Ocular Therapeutix is headquartered in BEDFORD, United States.